Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + etoposide + ifosfamide
- Development stage
- Unknown
- Lead developer
- Universitätsklinikum Münster
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Carboplatin + etoposide + ifosfamide is a combination chemotherapy regimen utilized in the SIOP CNS GCT II clinical trial for the treatment of intracranial germ cell tumors (GCTs) in children and young adults. This regimen, often administered in alternating cycles (e.g., etoposide/carboplatin alternating with etoposide/ifosfamide), is designed to provide risk-adapted therapy to maintain high survival rates while minimizing long-term toxicity from radiation. Carboplatin and ifosfamide are alkylating agents that interfere with DNA replication by forming covalent bonds and cross-links, whereas etoposide is a semisynthetic derivative of podophyllotoxin that inhibits topoisomerase II, preventing DNA ligation and inducing cell cycle arrest. The trial, led by University Hospital Muenster, aims to optimize outcomes for both germinoma and non-germinomatous germ cell tumors through stratified chemotherapy and reduced-field radiotherapy.
- Other names
- CEI regimenSIOP CNS GCT II chemotherapy regimencarboplatin + etoposide + ifosfamide-University Hospital Muenster-intracranial germ cell tumor
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on carboplatin + etoposide + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + etoposide + ifosfamide.